US WorldMeds Acquires Orbus Therapeutics To Advance Eflornithine Brain Tumor Program
· pulse2.com · popularity 20/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at pulse2.com →
Summary
US WorldMeds Ventures has acquired Orbus Therapeutics, adding a late-stage investigational therapy for recurrent Grade 3 astrocytoma to its rare-disease pharmaceutical portfolio. Orbus is now a wholly owned subsidiary of US WorldMeds. The post US WorldMeds Acquires Orbus Therapeutics To Advance Eflornithine Brain Tumor Program appeared first on Pulse 2.0 .
Found in: Pulse 2.0. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 6.